PT  - JOURNAL ARTICLE
AU  - Masatoshi Hotta
AU  - Andrei Gafita
AU  - Johannes Czernin
AU  - Jeremie Calais
TI  - Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with <sup>177</sup>Lu-PSMA Therapy: A Multicenter Retrospective Analysis
AID  - 10.2967/jnumed.121.263441
DP  - 2022 Oct 01
TA  - Journal of Nuclear Medicine
PG  - 1484--1488
VI  - 63
IP  - 10
4099  - http://jnm.snmjournals.org/content/63/10/1484.short
4100  - http://jnm.snmjournals.org/content/63/10/1484.full
SO  - J Nucl Med2022 Oct 01; 63
AB  - The aim of the study was to assess the outcome of patients with metastatic castration-resistant prostate cancer treated with 177Lu-prostate-specific membrane antigen (PSMA) who would have been a screen failure (SF) in the VISION trial based on PSMA PET/CT criteria. Methods: We conducted a retrospective multicenter cohort study on 301 patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA. The patients were classified into eligible (VISION-PET-E) and SF (VISION-PET-SF) groups on the basis of the baseline PSMA PET/CT results. Prostate-specific antigen (PSA) response rates, PSA progression-free survival, and overall survival were compared. Results: Of 301 patients, 272 (90.4%) and 29 (9.6%) were VISION-PET-E and VISION-PET-SF, respectively. The VISION-PET-SF patients had a worse rate of ≥50% PSA decline (21% vs. 50%, P = 0.005) and PSA progression-free survival (2.1 vs. 4.1 mo, P = 0.023) and tended to have a shorter overall survival (9.6 vs. 14.2 mo. P = 0.16) than the VISION-PET-E patients. Conclusion: The VISION-PET-SF patients had worse outcomes than the VISION-PET-E patients. Our cohort did not include preexcluded patients (10%–15%) by local site assessments. Thus, 20%–25% of the patients may be SFs in unselected populations. Refinements in patient selection for 177Lu-PSMA are needed to optimize outcomes.